Name: Listing of biotech company arGEN-X on EnterNext in Brussels
Uploaded: 2014-07-10T09:19:54+0200
Description: As of 10 July 2014 arGEN-X is listed on the Brussels markets. To celebrate this event, Tim Van Hauwermeiren, CEO of arGEN-X, opened the markets with a Bell Ceremony. Hans de Haard, co-founder of arGEN-X, had the honor to write the first opening price on the blackboard. The reference price was fixed at 8.50 euro.

Search Contact

This page is available in multiple languages

Select Language

Back

10/07/2014

As of 10 July 2014 arGEN-X is listed on the Brussels markets. To celebrate this event, Tim Van Hauwermeiren, CEO of arGEN-X, opened the markets with a Bell Ceremony. Hans de Haard, co-founder of arGEN-X, had the honor to write the first opening price on the blackboard. The reference price was fixed at 8.50 euro.

arGEN-X specializes in researching and developing human monoclonal antibodies for the treatment of oncological, autoimmune and inflammatory diseases.
At the end of 2013, the company had a portfolio of 2 products in phase I of clinical development and 3 products in preclinical development phase.

The ticker code of arGEN-X is : ARGX.

If you would like to find out more : www.argen-x.com